Immunohistochemical expression of idh mutations in gliomas and its clinicopathological correlation

Authors

  • Asha Jyothi T Senior Resident, Department of Pathology, Osmania Medical College, Koti, Hyderabad, Telangana, India
  • M. Mark Edward Senior Resident, Department of Pathology, Osmania Medical College, Koti, Hyderabad, Telangana, India

Keywords:

IDH-1, Glioblastomas, Idh-1, Mutations, KI-67, Diagnosis, Prognostic markers

Abstract

Aim: To study the expression of IDH-1 mutations in gliomas, with histopathological correlation and its clinical significance and also study the prognostic implication of IDH-1 expression by comparing with WHO grading system and with KI-67 expression in glial tumors. Methodology: This is a prospective study over a period of 24 months (July 2017 – June 2019) to be conducted at Osmania General Hospital, Hyderabad. Immunohistochemistry (IHC) for IDH1 and KI-67 is performed on three micron sections utilizing standardized protocols IDH1 (clone H09) and KI-67(clone GM001), on all selected cases. Results: In the present study, among the 54 cases of gliomas in the present study, IDH-1 mutation were observed in overall 54% of gliomas. History of seizures and frontal location are significantly associated with IDH-1 expression. IDH-1 is expressed mostly in oligoastrocytic tumors, gemistocytic astrocytomas, anaplastic PXA, diffuse astrocytic tumors followed by oligodendroglial tumors, glioblastomas and least expressed in ependymal tumors.These mutations were not seen in pilocytic astrocytomas.Secondary glioblastomas showed more (71%) IDH-1 mutations than primary glioblastomas(16%). IDH-1 expression were most common in WHO grade II and III gliomas and are significantly associated with these mutations. The present study revealed Ki 67 labelling indices were comparable between gliomas of similar malignancy grade, and indices for high-grade gliomas (grade III/IV) were significantly higher than in low-grade (grade I/II) tumors.The p value between gradeII and grade IV was statistically significant. The Ki 67 labelling indices were slightly higher in IDH-1 negative cases i.e IDH-1 wild variants than IDH-1 positive cases. Conclusion: IDH-1 mutations in gliomas has potential as an independent prognostic marker and also helps in distinguishing primary from secondary GB & its potential for new therapies, testing for IDH1 mutations can enhance accuracy of glioma diagnosis and treatment.

Downloads

Published

2021-08-30

How to Cite

Asha Jyothi T, & M. Mark Edward. (2021). Immunohistochemical expression of idh mutations in gliomas and its clinicopathological correlation. International Journal of Health and Clinical Research, 4(15), 138–149. Retrieved from https://ijhcr.com/index.php/ijhcr/article/view/2452